156 related articles for article (PubMed ID: 8611043)
1. [The guideline for clinical trials proposed by Japan Society for Cancer Therapy (JSCT)].
Kurihara M
Gan To Kagaku Ryoho; 1996 Jan; 23(2):156-65. PubMed ID: 8611043
[TBL] [Abstract][Full Text] [Related]
2. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
Andoh M; Fujiwara Y; Shimada Y
Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. [Critics and proposals for the response criteria of the Japan Lung Cancer Society].
Ohnoshi T
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):311-5. PubMed ID: 2649004
[TBL] [Abstract][Full Text] [Related]
5. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
6. [Results of questionnaire to 56 medical institutions about clinical trials of cancer chemotherapy].
Kurihara M; Matsukawa M; Satoh A; Shimada K; Asaumi H
Gan To Kagaku Ryoho; 1999 Jun; 26(7):916-25. PubMed ID: 10396318
[TBL] [Abstract][Full Text] [Related]
7. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
8. [Globalization of clinical trials].
Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
[TBL] [Abstract][Full Text] [Related]
9. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
10. [New guidelines to evaluate the response to treatment "RECIST"].
Sasaki T
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2179-84. PubMed ID: 11142160
[TBL] [Abstract][Full Text] [Related]
11. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.
Beitz J; Gnecco C; Justice R
J Natl Cancer Inst Monogr; 1996; (20):7-9. PubMed ID: 8750460
[TBL] [Abstract][Full Text] [Related]
12. [Adverse drug reaction criteria of the Japan Society for Cancer Therapy].
Shibuya M
Gan To Kagaku Ryoho; 1997 Nov; 24(14):2036-41. PubMed ID: 9388511
[TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer.
; Pfister DG; Laurie SA; Weinstein GS; Mendenhall WM; Adelstein DJ; Ang KK; Clayman GL; Fisher SG; Forastiere AA; Harrison LB; Lefebvre JL; Leupold N; List MA; O'Malley BO; Patel S; Posner MR; Schwartz MA; Wolf GT
J Clin Oncol; 2006 Aug; 24(22):3693-704. PubMed ID: 16832122
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
15. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
Ratain MJ; Miller AA; McLeod HL; Venook AP; Egorin MJ; Schilsky RL
Clin Cancer Res; 2006 Jun; 12(11 Pt 2):3612s-6s. PubMed ID: 16740794
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
17. [Principle and practice of clinical phase III studies].
Morant R
Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870
[TBL] [Abstract][Full Text] [Related]
18. [Japan Clinical Oncology Group for cooperative cancer clinical trials and role of the statistical center in the management of cancer clinical trials].
Shimoyama M; Tajima K
Gan To Kagaku Ryoho; 1993 Dec; 20(16):2507-18. PubMed ID: 8279849
[TBL] [Abstract][Full Text] [Related]
19. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
[TBL] [Abstract][Full Text] [Related]
20. The ethics of phase 0 oncology trials.
Abdoler E; Taylor H; Wendler D
Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
